In the 12 months to Nov 8, 2026, on the open market: bought $323K of AGMB; sold $60K of TEM. Filed a median of 1 business day after the trade.
Open-market purchases and sales this filer reported on SEC Form 4, by the day traded. Insiders have two business days to file. A sale marked 10b5-1 was made under a plan adopted in advance. How to read these
Insider purchases above the line: $323KInsider sales below: $60K
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.
AGMBBought: AgomAb Therapeutics NV Nov 5, 202615,000 sharesfiled Nov 6, 20263 transactionsfiling$104K
TEMSold: Tempus AI, Inc. Nov 2, 2026370 sharesfiled Nov 4, 202630,474 shares held directly after, as filed10b5-1 planfiling$27K
AGMBBought: AgomAb Therapeutics NV Oct 21, 202610,000 sharesfiled Oct 22, 20262 transactionsfiling$89K
AGMBBought: AgomAb Therapeutics NV Oct 8, 20265,000 sharesfiled Oct 9, 202615,000 shares held directly after, as filedfiling$44K
AGMBBought: AgomAb Therapeutics NV Oct 6, 20265,000 sharesfiled Oct 7, 202610,000 shares held directly after, as filedfiling$44K
AGMBBought: AgomAb Therapeutics NV Oct 5, 20265,000 sharesfiled Oct 7, 20265,000 shares held directly after, as filedfiling$43K
TEMSold: Tempus AI, Inc. Sep 1, 2026250 sharesfiled Sep 3, 202630,844 shares held directly after, as filed10b5-1 planfiling$16K
TEMSold: Tempus AI, Inc. Aug 3, 2026370 sharesfiled Aug 5, 202631,094 shares held directly after, as filed10b5-1 planfiling$16K
Source: SEC Form 4 filings. Value is shares × the price reported on the filing; a filing whose price failed Lytir's check against the market price is left out, and a trade that related owners reported on separate forms is counted once. Filings can be late, amended or wrong at the source; see methodology.
